Clinical significance of Q waves in ischemic cardiomyopathy
| Autor: | E Rodenas Alesina, Santiago Aguadé-Bruix, N Pizzi, L Herrador, P Jordan, Ignacio Ferreira-González, C Espinet-Coll |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Ischemic cardiomyopathy Ejection fraction business.industry medicine.medical_treatment Ischemia General Medicine medicine.disease Revascularization Heart failure Internal medicine medicine Cardiology Radiology Nuclear Medicine and imaging Radionuclide imaging Clinical significance Myocardial infarction Cardiology and Cardiovascular Medicine business |
| Zdroj: | European Heart Journal - Cardiovascular Imaging. 22 |
| ISSN: | 2047-2412 2047-2404 |
| DOI: | 10.1093/ehjci/jeaa356.340 |
| Popis: | Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): CIBER-CV AIMS The scintigraphic translation of Q waves in patients with ischemic cardiomyopathy and LVEF METHODS AND RESULTS A retrospective study enrolling 487 consecutive patients (67,0 [57,4 – 75,4] years), with ischemic cardiomyopathy, LVEF 10% of ischemia and revascularization remained in Cox model both in the total cohort (aHR= 0,46 [0,24 – 0,86]), and in patients with Q waves (aHR = 0,27 [0,11–0,69]). CONCLUSION Patients with ischemic cardiomyopathy with Q waves have larger subendocardial scarring and more transmural necrosis, although correlation between Q waves and transmural scarring is poor. Revascularization if >10% ischemia is present is associated with a better prognosis. Ischemia burden should be assessed and accordingly treated in these patients, and no differences in management should be made in the presence of Q waves. Table 1. Cox proportional hazards model Total cohort (N = 471) Patients with Q waves (N = 315) aHR p-value 95% CI aHR p-value 95% CI Age (per year) 1,02 0,007 1,01 - 1,04 n.s. Diabetes mellitus 1,35 0,047 1,00 - 1,81 1,54 0,016 1,09 - 2,20 eGFR < 60 ml/min 1,59 0,005 1,15 - 2,21 1,96 10% 0,46 0,015 0,24 - 0,86 0,27 0,006 0,11 - 0,69 Cox regression for the primary endpoint (cardiovascular death, heart failure hospitalization or myocardial infarction), accounting for non-cardiovascular death as a competitive risk. Abstract Figure. Survival for the primary endpoint |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|